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Signaling lymphocyte activation molecule family (SLAMF) receptors are essential 
regulators of innate and adaptive immune responses. The function of SLAMF5/CD84, 
a family member with almost ubiquitous expression within the hematopoietic lineage 
is poorly defined. In this article, we provide evidence that in human monocyte-derived 
dendritic cells (moDCs) SLAMF5 increases autophagy, a degradative pathway, which 
is highly active in dendritic cells (DCs) and plays a critical role in orchestration of the 
immune response. While investigating the underlying mechanism, we found that 
SLAMF5 inhibited proteolytic degradation of interferon regulatory factor 8 (IRF8) a master 
regulator of the autophagy process by a mechanism dependent on the E3-ubiquitin 
ligase tripartite motif-containing protein 21 (TRIM21). Furthermore, we demonstrate 
that SLAMF5 influences the ratio of CD1a+ cells in differentiating DCs and partakes in 
the regulation of IL-1β, IL-23, and IL-12 production in LPS/IFNγ-activated moDCs in a 
manner that is consistent with its effect on IRF8 stability. In summary, our experiments 
identified SLAMF5 as a novel cell surface receptor modulator of autophagy and revealed 
an unexpected link between the SLAMF and IRF8 signaling pathways, both implicated 
in multiple human pathologies.
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inTrODUcTiOn
Macroautophagy (here referred to as autophagy) is a conserved catabolic pathway, whereby 
cytosolic contents are sequestered by de novo formed double-membrane-bound vesicles, called 
autophagosomes and carried to lysosomes for degradation. It is active at basal levels in most cell 
types to recycle macromolecules (1, 2) and to prevent accumulation of cytotoxic metabolites (3). 
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Beyond maintaining cellular homeostasis, autophagy improves 
cell autonomous and host defense mechanisms against a number 
of pathogens by regulating intracellular protein trafficking and 
degradation as well as antigen presentation (4, 5). In addition, 
autophagy guards against both untimely and excessive inflam-
matory reactions by influencing the activation and duration of 
inflammation via suppression of ROS accumulation and removal 
of danger signals as well as regulation of pro-inflammatory 
cytokine production (6).
Dendritic cells (DCs) continuously migrate from tissues to 
lymph nodes to present antigens to antigen-specific T cells. The 
DC pool of non-lymphoid organs is maintained by constant 
replenishment from circulating monocytes (7, 8) whose differ-
entiation into DCs is dependent on the induction of autophagy 
(9). DCs exploit autophagy to display cytoplasmic self- or for-
eign antigens on MHC II molecules for CD4+ T cells (10). This 
mechanism, depending on the presence or absence of danger 
signal-induced co-stimulation, contributes to the initiation of 
a pathogen-specific immune response and to establishment or 
maintenance of peripheral tolerance, respectively (11). The rate 
of autophagy therefore must be stringently controlled to adapt 
to the actual immune context. Stimulation of DCs by LPS has 
been shown to transiently reduce autophagy and its associated 
functions (12), presumably to diminish presentation of self-
antigens and focus the immune response against an emerging 
environmental threat. However, as all immune responses, 
including TLR-mediated functions have the potential to convey 
damage to host tissues, the recovery of autophagy, reestablish-
ing its anti-inflammatory effects is increasingly recognized as an 
essential component of the maintenance of host tissue integrity.
Recent work of the Ozato laboratory identified interferon 
regulatory factor 8 (IRF8) as a positive regulator of autophagy in 
murine macrophages and DCs exposed to various stress signals, 
including starvation, exposure to TLR ligands or infection with 
Listeria monocytogenes (13). Furthermore, their earlier work 
demonstrated that stimulation of murine macrophages with 
LPS/FNγ induced secretion of IL-12 that was fully dependent 
on IRF8 (14). The amount and activity of the IRF8 protein were 
found to be controlled by ubiquitin ligases (TRIM21, c-Cbl), the 
p62 ubiquitin-binding protein (Sequestosome-1) as well as the 
deubiquitinase USP4, regulating its proteasomal degradation 
(15–18). The tasks of IRF8 as a regulator of autophagy or its role 
in human monocyte-derived dendritic cells (moDCs) functions 
have not been properly addressed.
Members of the cell surface-expressed signaling lymphocyte 
activation molecule family (SLAMF) receptors (19–21) have been 
shown to regulate autophagy. SLAMF1 (CD150) and SLAMF4 
(CD244 or 2B4) were reported to bind to the Beclin-1/Vps34 
autophagy-associated complex (22–24) responsible for gen-
eration of PI(3)P, a phospholipid involved in autophagic vesicle 
nucleation. SLAMF1 increased the autophagic flux in human 
chronic lymphocytic leukemia cells (25) via stabilization of the 
above autophagic macrocomplex. On the contrary, SLAMF4 was 
identified as an inhibitor of starvation- and rapamycin-induced 
autophagy in human lymphoblastoid cell lines and in murine 
bone marrow-derived macrophages via reducing Vps34 lipid 
kinase activity (23).
SLAMF5 is a self-ligand receptor broadly expressed on the 
surface of hematopoietic cells that during cell–cell communica-
tion acts both as an adhesion and signaling molecule (26–28). 
Although its cell surface expression on both the myeloid and 
plasmacytoid subsets of DCs have been established (29, 30), its 
function in these cells has not been addressed.
Overall, regulatory circuits of autophagy and inflammation 
are interconnected at multiple levels (4–6), thus molecules 
involved in the regulation of autophagy have a major impact on 
the outcome of the immune response. Identification of autophagy 
regulators, cell surface receptors, readily accessible for antibodies 
in particular, may provide excellent targets to modulate autophagy 
in various disease states.
In this report, we examined the effect of SLAMF5 on human 
moDC responses induced by LPS/IFNγ, frequently used as a 
model of infection with Gram-negative bacteria. We identify 
SLAMF5 as a novel cell surface-expressed regulator of basal 
autophagy that responding to inflammatory signals fine-tunes 
cytokine production of human moDCs via affecting a pathway 
responsible for proteasomal degradation of IRF8.
MaTerials anD MeThODs
In Vitro Differentiation of moDc  
and rna interference
Monocytes were isolated from human leukocyte concentrates 
(buffy coats) obtained from healthy blood donors drawn at the 
Regional Blood Center of Hungarian National Blood Transfusion 
Service (Debrecen, Hungary) in accordance with the written 
approval of the Director of the National Blood Transfusion 
Service and the Regional and Institutional Ethics Committee 
of the University of Debrecen, Faculty of Medicine (Debrecen, 
Hungary). Peripheral blood mononuclear cells (PBMC) were 
separated by Ficoll Paque (GE Healthcare) gradient centrifuga-
tion, and then monocytes were purified by magnetic cell isolation 
using CD14 antibody-coated magnetic microbeads (Miltenyi 
Biotech) according to the manufacturer’s protocol. The following 
siRNAs were used for gene silencing by transfection of freshly 
isolated primary human monocytes:
SLAMF5 sense: 5′-UGGCUAUGUUCUUUCUGCUUGUUC 
U-3′,
SLAMF5 antisense: 5′-AGAACAAGCAGAAAGAACAUAGC 
CA-3′,
Negative control for SLAMF5 sense: 5′-UGGUAUGCUUUCUG 
UUCGUUUCUCU-3′,
Negative control for SLAMF5 antisense: 5′-AGAGAAACGAA 
CAGAAAGCAUACCA-3′.
(Stealth™ RNAi, ThermoFisher Scientific), IRF8 Silencer 
Select siRNA (Assay ID: s7100), TRIM21 Silencer Select siRNA 
(Assay ID: s13462), and non-targeted Silencer Select Negative 
Control No 1. siRNA (ThermoFisher Scientific). The siRNA 
duplexes were delivered by electroporation using GenePulser 
Xcell instrument (Bio-Rad Laboratories). Following transfection, 
monocytes were cultured at a density of 106 cells ml−1 on 24-well 
plates in complete RPMI-1640 medium containing 10% fetal 
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bovine serum (both from ThermoFisher Scientific), 100 U ml−1 
penicillin and 100  ng  ml−1 streptomycin (both from Sigma-
Aldrich), supplemented with 80  ng  ml−1 GM-CSF (Gentaur 
Molecular Products), and 100 ng ml−1 IL-4 (PeproTech) for 5 days 
to generate moDCs. Culture medium was replenished on day 2 
by removing three-quarters of the supernatant and replacing it 
by complete medium containing GM-CSF and IL-4.
receptor cross-linking
For SLAMF5 stimulation moDCs adjusted to 107 ml−1 were sus-
pended in complete RPMI-1640 medium containing 10 µg ml−1 
anti-SLAMF5 antibody (clone 152-1D5; LifeSpan BioSciences, 
Cat. No. LS-C134663) or an IgG isotype control antibody 
(BioLegend, Cat. No. 400124) at 4°C for 45 min. Thereafter, fol-
lowing thorough washing procedures, cells were reseeded into 
24-well cell culture plates and incubated in complete medium 
in the presence of 10  µg  ml−1 F(ab′)2 of goat anti-mouse IgG 
(Jackson ImmunoResearch Laboratories, Cat. No. 115-006-062) 
at 37°C for 2 h.
cell stimulation
Dendritic cell maturation was induced by simultaneous addi-
tion of 100  ng  ml−1 LPS (ultrapure lipopolysaccharide from 
Salmonella minnesota R595, Cat. No. tlrl-smlps) and 10 ng ml−1 
recombinant human IFNγ (PeproTech, Cat. No. 300-02) for the 
indicated time periods. For autophagy induction, moDCs were 
exposed to 50 nM rapamycin (Merck, Cat. No. 553210) for 4 h. 
The optimal concentration of rapamycin was determined as one 
that readily increased LC3-II levels without significant toxicity. In 
some experiments, cells were incubated with 20 nM bafilomycin 
A1 (BafA1) (InvivoGen, Cat. No. tlrl-baf1) or 1  µM MG132 
(SelleckChem, Cat. No. S2619) for the last 2 h.
Western Blot analysis
For western blot analysis protein extracts were obtained by 
lysing cells in Laemmli buffer. The samples were resolved by 
SDS-PAGE and transferred electrophoretically onto nitrocel-
lulose membranes (Bio-Rad Laboratories). Non-specific bind-
ing was blocked by TBS–Tween–5% non-fat dry milk, and then 
the membrane was probed with anti-SLAMF5 (clone H128), 
anti-β-actin (Cat. No. sc-47778), anti-Akt1 (Cat. No. sc-5298), 
anti-ubiquitin (Cat. No. sc-9133), and anti-TRIM21 (Cat. No. 
sc-25351) all from Santa Cruz Biotechnology, anti-phospho-
p70S6K Thr389 (Cat. No. 9206), anti-p70S6K (Cat. No. 
9202), and anti-IRF8 (Cat. No. 5628S) all from Cell Signaling, 
anti-phospho-Akt Ser473 (R&D Systems, Cat. No. AF887), 
anti-EAT-2 (LifeSpan BioSciences, Cat. No. LS-C169054) or 
anti-LC3 (Novus Biologicals, Cat. No. NB100-2220) antibod-
ies followed by washing and incubation with anti-mouse or 
anti-rabbit horseradish peroxidase-conjugated secondary 
antibodies (GE Healthcare). Specific signals were detected 
on X-ray films using the ECL system (SuperSignal West Pico/
Femto chemiluminescent substrate; ThermoFisher Scientific). 
Protein bands were scanned, and band densities were deter-
mined using Kodak 1D Image Analysis software, version 3.6. 
Relative density was calculated by normalizing to β-actin band 
intensities. The level of phosphorylation was normalized to 
the total amount of the same protein present in the samples.
rna extraction, reverse Transcription 
and real-time Quantitative Pcr
Extraction of total RNA was performed using TRI-Reagent 
(Molecular Research Center) according to the protocol 
of the manufacturer. Total RNA was treated with DNase I 
(ThermoFisher Scientific), and then cDNA was synthesized 
using the High Capacity cDNA Reverse Transcription kit of 
Applied Biosystems. Quantitative PCR was performed with the 
ABI StepOne Real-Time PCR System using Dream Taq DNA 
Polymerase (ThermoFisher Scientific) and gene-specific assay 
for IRF8 (ThermoFisher Scientific, Assay ID: Hs00175238_m1) 
according to the manufacturer’s instructions. The cycle threshold 
(Ct) values were determined using the StepOne v2.1 Software 
(Applied Biosystems). The relative amount of mRNA (2−ΔCt) was 
obtained by normalizing to the cyclophilin housekeeping gene in 
each experiment.
Flow cytometry
Viability of the cells was determined on day 5 by 7-aminoactino-
mycin-D (7-AAD 10 µg ml−1; Sigma-Aldrich) staining for 15 min 
immediately before flow cytometry. Cell surface protein expres-
sion was detected with FITC-labeled monoclonal antibodies 
against HLA-A, B, C (Sony Biotechnology), HLA-DQ, HLA-DR, 
and CD40 (all from BioLegend), PE-labeled monoclonal antibod-
ies against SLAMF5 (BioLegend, clone 1.21), CD14 and CD86 
(both from R&D Systems), DC-SIGN (Sony Biotechnology), and 
APC-labeled monoclonal antibodies against CD1a (BioLegend). 
Isotype-matched control antibodies were obtained from 
BioLegend. Measurement of autophagy was performed using 
the CYTO-ID Autophagy detection kit (Enzo Life Sciences) 
according to the manufacturer’s instructions. Briefly, 2 × 105 cells 
were incubated with CYTO-ID Green autophagy detection dye 
(1:2,000) for 30 min at 37°C, then cells were washed and imme-
diately subjected to flow cytometry. Fluorescence intensities 
were measured with a FACS Calibur cytometer (BD Biosciences) 
excluding cell debris by forward/side scatter gating. In case of 
CD1a analysis, the positive gate was set excluding the area stain-
ing with the isotype-matched control mAb. Relative fluorescence 
and the percentage of positive cells in samples were determined 
with the FlowJo software.
confocal Microscopy
For live cell confocal microscopy, 2 ×  105  cells were cultured 
on 8-well μ-Slides (chambered coverslip, ibidi GmbH). Where 
indicated, 50  µM Chloroquine (Enzo Life Sciences) was used 
to inhibit autophagosome turnover. Cells were stained with 
CYTO-ID Green Detection Reagent (1:2,000) and Hoechst 
33342 Nuclear Stain (1:2,000) for 30 min at 37°C. Next, cells were 
washed as recommended by the manufacturer and visualized 
immediately by a Zeiss LSM880 confocal microscope equipped 
with an NA = 1.2, 40× water immersion objective. Hoechst was 
excited at 405 nm and detected in the 410–485 nm range, while 
CYTO-ID was excited at 488 nm and detected in the 499–562 nm 
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range. Scanning was done at a 0.86 μs/pixel rate in multitrack/
line switch mode to avoid spectral spillover. Pinhole was set to 
32  µm, equivalent to 1  Airy unit. Lateral (x–y) sampling was 
0.87 μm/pixel. Images were obtained within 45 min after stain-
ing to avoid loss of fluorescence due to leakage of the dye.
elisa
The concentrations of IL-1β and IL-12 in culture supernatants were 
determined by BD-OptEIA Human ELISA kits (BD Biosciences), 
and the level of IL-23 was measured with the human IL-23 ELISA 
Ready-Set Go kit (eBioscience) according to the manufacturer’s 
instructions. Absorbance measurements were carried out by a 
Synergy HT microplate reader at 450 nm.
statistical analysis
We performed parallel experiments and compared matching 
observations on control and silenced cells, thus the research 
design meets the assumptions of the paired t-test. However, fol-
lowing monocyte separation, we randomly assigned cells from 
the same donor to either the knockdown or control groups, 
cultured the transfected cells separately for 5  days, and then 
acquired post-intervention data from the two populations. For 
these reasons, we considered our samples independent and 
determined the statistical differences between the experimental 
groups by unpaired two-tailed Student’s t-test. p-values of <0.05 
were considered to be statistically significant. All data were 
derived from at least three independent experiments and are 
expressed as mean ±  SD. Data were analyzed with the Prism 
software (GraphPad).
resUlTs
slaMF5 is Upregulated during 
Differentiation and activation  
of human moDcs
In the process of in  vitro differentiation of moDCs, expres-
sions of several receptors with immune modulatory function 
are upregulated. We found that SLAMF5 is strongly induced 
when monocytes are differentiated into DCs by GM-CSF and 
IL-4 suggesting that SLAMF5 is required for the proper func-
tions of immature DCs (Figure  1A). To evaluate the impact 
of SLAMF5–SLAMF5 interaction on moDC functions, we 
performed RNA interference targeting SLAMF5 on freshly 
isolated monocytes. Based on flow cytometry and western blot 
analyses, SLAMF5 expression was reduced by 80–95%, and 
silencing was maintained throughout the entire course of dif-
ferentiation (Figure 1B). Although Binsky et al. have recently 
published that SLAMF5 acts as a survival receptor in chronic 
lymphocytic leukemia cells and its downregulation results in 
receptor induced cell death (31), under our experimental condi-
tions neither the viability of moDCs nor the yield of differentia-
tion was affected by SLAMF5 silencing (Figure 1C). Next, we 
analyzed whether SLAMF5-deficient cells display any defects in 
moDC differentiation by measuring CD14, highly expressed on 
monocytes but downregulated on moDCs, as well as DC-SIGN 
(CD209), typically expressed by differentiated DCs. As shown in 
Figure 1D, cell surface expression of CD14 and DC-SIGN was 
identical in SLAMF5-silenced and control moDCs indicating 
that even grossly diminished levels of SLAMF5 did not affect 
the differentiation of monocytes into moDCs.
As simultaneous LPS and IFNγ stimuli further increased its 
expression level in moDCs (Figure 1A), we analyzed the potential 
role of SLAMF5 as a modulator of DC activation in response to 
LPS/IFNγ. Downregulation of SLAMF5 expression nevertheless 
was not accompanied by severely impaired LPS/IFNγ-response 
as SLAMF5-silenced moDCs retained their capacity to enhance 
cell surface expression of markers associated with DC maturation 
in response to LPS/IFNγ stimulation. The amounts of HLA-A, B, 
C and HLA-DQ increased to the same extent after stimulation of 
control and SLAMF5-silenced cells. In addition, the expression 
of the co-stimulatory receptors CD40 and CD86 was identical 
in control and knockdown cells (Figure S1A in Supplementary 
Material). Interestingly, silencing of SLAMF5 at an early phase of 
moDC differentiation led to a moderate, but significant decrease 
in the subset of CD1a+ DCs (Figure  1E). Further analysis of 
the above DC-maturation markers in the CD1a+ and CD1a− 
DC-subsets, however, revealed no significant differences in 
response to SLAMF5 silencing (Figures S1B–D in Supplementary 
Material).
slaMF5 enhances autophagy in moDcs
In light of the recently established link between autophagy and 
SLAMF receptors (23, 25), we examined whether SLAMF5 
partakes in the process of autophagy in resting or activated DCs. 
Microtubule associated protein 1 light chain 3 beta (LC3 here-
after) is widely used to monitor autophagy. During autophagy 
induction the processed LC3 is covalently coupled with phos-
phatidylethanolamine in the newly forming autophagosomal 
membrane (32). The cleaved cytosolic LC3 (called LC3-I) and the 
lipid-modified, autophagosome-associated LC3 (LC3-II) can be 
identified by their different electrophoretic mobility and the level 
of LC3-II correlates with the amount of autophagosomes (33). As 
displayed in Figure 2A, we detected lower LC3-II/β-actin ratios 
in SLAMF5-silenced moDCs than in control cells indicating the 
importance of SLAMF5 in maintenance of basal autophagy. To 
evaluate kinetic changes in autophagy during DC activation, 
we treated control and SLAMF5 knockdown moDCs with LPS/
IFNγ for 4 and 8 h. The expected transient, activation-dependent 
decrease in LC3-II levels (10, 12) was apparent 4 h past treatment 
with LPS/IFNγ both in control and SLAMF5-silenced moDCs. 
At 8  h past stimulation, however, LC3-II levels recovered in 
control but not in SLAMF5-silenced cells (Figure  2A; Figure 
S2A in Supplementary Material). Since LC3-II molecules local-
ized in the inner membrane of autophagosomes are degraded 
during the autophagic process, lower levels of LC3-II may result 
from either decreased autophagosome formation or increased 
autophagic degradation (33). When BafA1, an inhibitor of 
autophagosome–lysosome fusion and lysosomal acidification 
(34) was applied LC3-II levels remained lower in the absence of 
SLAMF5 compared with controls (Figure 2B). As a control for 
the activity of BafA1, the extent of LC3-II accumulation is shown 
side by side in BafA1-treated and untreated samples (Figure S2B 
in Supplementary Material). This observation implies that rather 
FigUre 1 | The effect of SLAMF5 silencing on the phenotype of moDCs. (a) Cell surface expression of SLAMF5 on monocytes and on GM-CSF/IL-4-differentiated 
moDCs treated or not with LPS/IFNγ was assessed by flow cytometry. (B) Monocytes were transfected with the indicated siRNAs and differentiated into moDCs. On 
day 5, SLAMF5 expression was measured by flow cytometry and western blot analysis. β-actin was used as protein loading control. (c) Viability of control and 
SLAMF5 knockdown moDCs was determined by 7-aminoactinomycin-D (7-AAD) dye exclusion. Bar graphs indicate percentage of cells negative for 7-AAD (left 
panel) and the total number of moDCs differentiated from 106 monocytes (right panel). (D) Expression levels of CD14 and DC-SIGN in control and SLAMF5 
knockdown moDCs were measured by flow cytometry. Representative histograms show protein expression in control (thin line with gray shading) and knockdown 
cells (bolded black line) or staining with isotype control antibody (thin gray line). Bars show the relative fluorescence intensity values of CD14 and DC-SIGN, 
calculated using the respective isotype-matched control antibodies. The results shown are taken from four independent donors. (e) Representative histograms 
show CD1a expression in control (thin line with gray shading) and SLAMF5-silenced (bolded black line) moDCs. Bars show the percentage of CD1a+ cells. Data are 
presented as means ± SD of six independent experiments. Error bars indicate SD (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001; ns, not significant).
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than being involved in the maturation process of autophagosomes, 
SLAMF5 appears to be a positive regulator of autophagosome 
biogenesis. To further support SLAMF5-mediated regulation of 
autophagy we used CYTO-ID, a fluorescent dye that selectively 
labels autophagic vacuoles in live cells (35) and thus can be 
readily quantified by flow cytometry (36). In agreement with 
the results obtained by LC3 blotting, fluorescence intensity of 
CYTO-ID was significantly lower in SLAMF5 knockdown cells 
FigUre 2 | SLAMF5-mediated enhancement of dendritic cell autophagy under steady-state conditions and in response to LPS/IFNγ activation. Control and 
SLAMF5-silenced moDCs were stimulated or not with LPS/IFNγ for the indicated time periods in the absence [(a) cropped] or in the presence of 20 nM bafilomycin 
A1 (BafA1) applied for the last 2 h (B). Conversion of LC3 was determined by western blotting. A representative immunoblot of four independent experiments is 
shown on the left; ratios of LC3-II and β-actin determined by densitometry are shown in the right panels. (c) Control and SLAMF5-depleted moDCs were stained 
with CYTO-ID. Fluorescence intensity was determined by flow cytometry. Graph depicts the relative fluorescence intensity of CYTO-ID obtained in four independent 
experiments (D,e). moDCs were conditioned with 10 μg ml−1 SLAMF5-specific or control antibodies followed by cross-linking with 10 μg ml−1 F(ab′)2 fragment of 
goat anti-mouse IgG, then stimulated with LPS/IFNγ for 8 h in the absence (D) or in the presence (e) of 20 nM BafA1 applied for the last 2 h of the experiment. LC3 
and β-actin levels were analyzed by western blotting; a representative blot and the mean ratios of LC3-II to β-actin from three independent experiments are shown. 
Data are expressed as the mean ± SD (*p < 0.05 and **p < 0.01).
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than in controls (Figure 2C). Confocal microscopy analysis of 
CYTO-ID staining revealed punctate structures, the number of 
which increased in the presence of chloroquine (Figure S2C in 
Supplementary Material). Chloroquine inhibits maturation of 
autophagosomes by affecting lysosomal acidification, thereby 
resulting in accumulation of large CYTO-ID positive compart-
ments (37). Therefore, the fluorescence signal detected by flow 
cytometry indeed resulted from accumulation of the dye in 
autophagic vacuoles.
If SLAMF5 is an important regulatory module of the 
autophagy pathway, increased signaling via SLAMF5 is expected 
to enhance autophagy. To test this, we used the SLAMF5-specific 
agonistic antibody 152.1D5 reported to induce SLAMF5 signal-
ing both in T cells (38) and in chronic lymphocytic leukemia cells 
(31). Cross-linking of cell surface SLAMF5 with the 152.1D5 
monoclonal antibody greatly increased LC3-II levels both in the 
presence and absence of BafA1 (Figures  2D,E). To exclude Fc 
receptor-mediated effects, an isotype-matched mAb was used as 
control in each experiment.
Collectively, these data demonstrate that SLAMF5 in moDCs 
potentiates basal autophagy and the recovery of autophagy after 
LPS/IFNγ activation.
autophagy Defect Observed in the 
absence of slaMF5 is not Mended  
by rapamycin
mTOR is one of the key negative regulators of autophagy (39). 
One potential mechanism by which SLAMF5 could enhance the 
level of autophagy was inhibition of the mTORC1 complex. To 
examine this scenario we used rapamycin (RAPA), a specific 
inhibitor of the mTORC1 complex and a well-known inducer 
FigUre 3 | Enhancement of autophagy by SLAMF5 is not mediated by inhibition of the mTORC1 complex. (a) The autophagy-inducer rapamycin was applied to 
control or SLAMF5-silenced cells for 4 h. Autophagy was monitored by western blot analysis using an LC3-specific antibody. A representative blot of four 
independent experiments is shown on the left, and densitometry of LC3-II to β-actin ratios is depicted on the right panel. (B) Cells were treated as described in 
panel (a), except that they were cultured in the presence of 20 nM bafilomycin A1 (BafA1) for the last 2 h. Data were analyzed as described in panel (a). (c) 
SLAMF5-silenced or control monocyte-derived dendritic cells were activated with LPS/IFNγ, and phosphorylation of Akt and p70S6K was analyzed with 
immunoblotting. Representative blots of four independent experiments are shown. The phospho-proteins were normalized to the total levels of Akt1 and p70S6K. 
Data are expressed as mean ± SD (**p < 0.01 and ***p < 0.001; ns, not significant).
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of autophagy (39). Control and SLAMF5-silenced moDCs 
were treated with rapamycin for 4  h either in the presence or 
absence of BafA1. As shown in Figures  3A,B, the autophagy 
defect remained apparent in SLAMF5-silenced cells even when 
mTORC1 was suppressed, suggesting that SLAMF5-mediated 
regulation of autophagy is independent of mTOR activity. To 
further test this scenario, SLAMF5-silenced and control moDCs 
were activated with LPS/IFNγ, and phosphorylation of Akt, 
a kinase upstream of mTOR, and of the mTOR target protein 
p70S6K was monitored by western blot analysis. If SLAMF5 
increases autophagy by inhibition of mTOR activity, silencing 
of SLAMF5 should potentiate the Akt/mTOR/p70S6K path-
way resulting in increased phosphorylation of these proteins. 
However, as shown in Figure 3C, the amounts of phospho-Akt 
and phospho-p70S6K were comparable in SLAMF5-silenced 
and control cells. The fact that rapamycin failed to restore the 
autophagy defect present in SLAMF5-silenced cells together 
with our findings that phosphorylation of Akt, and p70S6K 
was unaffected at diminished SLAMF5 protein levels strongly 
suggest that mTOR is not the main mediator of the autophagy 
pathway modulated by SLAMF5.
slaMF5 regulates autophagy via 
Preventing Proteasomal Degradation  
of irF8
Recently, Gupta and colleagues reported that IRF8 is expressed 
under steady-state conditions in murine bone marrow-derived 
DCs and its expression level is significantly increased in 
response to LPS/IFNγ treatment. Moreover, IRF8 was shown to 
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switch on the expression of many genes involved in all phases of 
autophagy (13). Based on the central role of IRF8 in the process 
of autophagy, we hypothesized that the molecular mechanism 
by which SLAMF5 promotes autophagy may involve the regula-
tion of IRF8 activity. To test this, first, we silenced SLAMF5 and 
analyzed induction of IRF8 expression in response to treatment 
with LPS/IFNγ. As shown in Figure 4A, the amount of IRF8 pro-
tein in SLAMF5-silenced moDCs was significantly decreased. 
To gain more insight into the effects of decreased IRF8 levels 
on moDC differentiation and functions, IRF8 expression was 
silenced using an IRF8-specific siRNA (Figure 4B). Interestingly, 
we found that silencing of IRF8, a lineage determining factor for 
myeloid cells, had no significant effect on the downregulation 
of CD14 expression or the induction of DC-SIGN expression 
associated with the differentiation process in the presence of 
IL-4 and GM-CSF (Figure  4C). Moreover, IRF8 expression 
was also not requisite for the expression of SLAMF5 that was 
significantly increased in IRF8-silenced cells (Figure S3 in 
Supplementary Material).
Importantly, the shift toward CD1a− moDCs observed in 
SLAMF5-silenced cells was evident in IRF8 knockdown cells 
(Figure 4D), consistent with a previous study by Granato et al., 
reporting that interference with the autophagic process in 
monocytes resulted in reduced expression of CD1a on moDCs 
(40). To test whether IRF8 acts as a regulator of autophagy in 
human moDCs, the intensity of autophagy was compared in 
IRF8-silenced and control moDCs. In line with its function 
in murine macrophages and DCs, and its suspected role as a 
mediator of SLAMF5’s effects, IRF8-silenced moDCs showed 
significantly decreased autophagy compared with controls. As 
shown in Figures  4E,F, the amount of LC3-II as well as the 
fluorescence intensity of CYTO-ID were significantly decreased 
(Figure 4G). These findings demonstrate that similar to murine 
bone marrow-derived DCs, IRF8 is used for the regulation of 
autophagy in human moDCs. To determine whether SLAMF5 
and IRF8 are part of the same or different autophagy regulatory 
pathways, SLAMF5 was cross-linked with the above described 
152.1D5 mAb antibody on moDCs transfected with control or 
IRF8-specific siRNA. As shown in Figure  4H, cross-linking of 
SLAMF5 significantly increased autophagy in moDCs trans-
fected with the control oligonucleotides; however, this induction 
was dependent on the presence of IRF8. This observation estab-
lished IRF8 as part, and a downstream element of the SLAMF5 
autophagy regulatory pathway.
Protein levels are determined by the rate of transcription 
followed by translation as well as the rate of protein degrada-
tion. When SLAMF5-silenced and control moDCs were 
activated by LPS/IFNγ, both the kinetics and the intensity of 
IRF8-transcription were found to be identical between silenced 
cells and controls (Figure 5A) indicating the lack of SLAMF5-
mediated regulation at the level of IRF8-transcription. Given that 
IRF8 activity and its stability are regulated by polyubiquitination 
and subsequent proteasomal degradation (15, 17), we examined 
whether degradation of IRF8 by the proteasome was affected by 
SLAMF5. When moDCs were activated by LPS/IFNγ in the pres-
ence of the proteasome inhibitor MG132, IRF8 levels in SLAMF5 
knockdown moDCs were completely restored (Figure  5B). 
As a control, enrichment of ubiquitin-linked proteins in the 
presence of MG132 was confirmed by probing identical blots 
with a ubiquitin-specific antibody (Figure S4 in Supplementary 
Material). Since ubiquitination of IRF8 by the E3-ubiquitin 
ligases TRIM21 (Ro52) (15) and casitas B-lineage lymphoma 
(c-Cbl) (17) has been described in murine macrophages, we 
tested whether IRF8 degradation in SLAMF5-silenced cells 
required the participation of these ligases. To this end, first, 
we confirmed induction of TRIM21 in response to LPS/IFNγ 
(Figure S5 in Supplementary Material) and its silencing in the 
presence of TRIM21 gene-specific siRNA (Figure  5C). Next, 
SLAMF5 alone, or in combination with TRIM21, was silenced, 
and the level of IRF8 protein was measured in moDCs treated 
with LPS/IFNγ. As shown in Figure  5D, IRF8 degradation in 
SLAMF5-silenced moDCs was blocked when cells were co-
transfected with the TRIM21-specific, but not with the control 
oligo. This finding clearly showed that increased degradation of 
IRF8 in the absence of SLAMF5 was dependent on the presence 
of TRIM21. In similar experiments, IRF8 was not rescued from 
degradation by silencing the E3-ubiquitin ligase c-Cbl (data not 
shown).
Two single SH2 domain-containing proteins, the SLAM-
associated protein and the Ewing sarcoma activated tran-
script-2 (EAT-2) are major transducers of SLAMF-receptor 
signaling (19, 41, 42). Based on its reported expression in 
antigen-presenting cells (43) and a recent report describing it 
as an enhancer of the autophagy process (23), EAT-2 emerges 
as a potential adapter transmitting SLAMF5 signals. However, 
when EAT-2 expression was thoroughly examined in our 
model, we found EAT-2 expressed in human monocytes, but 
abruptly downregulated in response to the used DC differen-
tiation signals. The EAT-2 protein was absent both in resting 
and LPS/IFNγ-activated moDCs (Figure S6 in Supplementary 
Material), indicating that SLAMF5 drives autophagy in moDCs 
in an EAT-2-independent manner.
Taken together, unlike its induction of gene expression and 
translation, the stability of the IRF8 protein is strongly affected 
by the presence of SLAMF5 that appears to control the activity 
of TRIM21. These data also support a mechanism connecting 
SLAMF5 to autophagy as part of the regulatory cascade sustain-
ing activity of IRF8, a major transcription factor of autophagy-
related genes.
SLAMF5 and IRF8 silencing in Monocytes 
results in Development of moDcs with 
Overlapping changes in cytokine 
secretion
To further support our hypothesis that the impact of SLAMF5 
silencing on DC functions is the consequence of IRF8 degrada-
tion, hereinafter, we examined whether depletion of IRF8 could 
induce similar functional changes to those seen in SLAMF5-
silenced moDCs. Given the well-characterized role of autophagy 
in the inflammatory response, the contribution of SLAMF5 and 
IRF8 to cytokine production of moDCs was examined. To this 
end, we measured the amount of pro-inflammatory cytokines 
in the supernatant of control and knockdown moDCs exposed 
FigUre 4 | Continued
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FigUre 5 | Proteasomal degradation of IRF8 is dependent on the E3-ubiquitin ligase TRIM21. (a) Kinetics of IRF8 mRNA expression were analyzed by quantitative 
PCR in five donors after treatment of control and SLAMF5 knockdown moDCs with LPS/IFNγ for the indicated time periods. (B) Control and SLAMF5 knockdown 
moDCs were stimulated with LPS/IFNγ for 8 h and, where indicated, 1 µM MG132 was added 2 h before harvesting. A representative immunoblot (left) and 
densitometric quantification (right) of three immunoblots from independent experiments are shown. (c) Efficiency of TRIM21 knockdown was tested on day 5 by 
western blot analysis; a representative blot is shown with β-actin as loading control. (D) SLAMF5 expression alone or together with TRIM21 expression was silenced 
by transfection of moDCs with the indicated set of gene-specific or control siRNAs. Transfected cells were activated with LPS/IFNγ for the indicated time periods. 
IRF8 protein levels were determined by western blotting. One representative blot (left) and densitometry of three independent experiments (right) are shown. Data are 
expressed as the mean ± SD (*p < 0.05; ns, not significant).
FigUre 4 | SLAMF5 controls the level of IRF8 protein, a positive regulator of autophagy in moDCs. (a) moDCs transfected with either control or an SLAMF5-
specific siRNA were treated with LPS (100 ng ml−1) and IFNγ (10 ng ml−1) for the indicated time periods. IRF8 protein level was measured by immunoblotting, and 
the ratio of IRF8/β-actin was quantified from five independent experiments. (B) Efficiency of IRF8 knockdown was tested on day 5 by western blot analysis; a 
representative blot is shown with β-actin as loading control. (c) Expression levels of CD14 and DC-SIGN as well as CD1a (D) were measured in control and IRF8 
knockdown moDCs by flow cytometry. Bars show the relative fluorescence intensity values or the percentage of positive cells. The results shown are taken from 
three independent experiments. LC3-II expression was measured in control or IRF8-silenced moDCs by immunoblotting in the absence (e) or in the presence of 
bafilomycin A1 (BafA1) (F). One representative of three experiments is shown. Bar charts display the ratio of LC3-II/β-actin. (g) CYTO-ID staining of control and 
IRF8-silenced moDCs from three donors was analyzed by flow cytometry. (h) CYTO-ID staining of control and IRF8-silenced moDCs in which SLAMF5 was 
cross-linked with the SLAMF5-specific agonistic antibody 152.1D5 as described in Section “Materials and Methods.” Data are expressed as the mean ± SD 
(*p < 0.05 and **p < 0.01, ns, not significant).
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FigUre 6 | Cytokine production of SLAMF5- and IRF8-silenced moDCs. SLAMF5- (a) or IRF8-silenced (B) moDCs were left untreated or stimulated with LPS/IFNγ, 
and their cytokine productions were compared with cells transfected with control oligonucleotides. Cytokine concentrations in supernatants were determined at 8 h 
(IL-1β and IL-23) or 12 h (IL-12) by ELISA. Lack of bars indicates cytokine secretion below the limit of sensitivity for the ELISA. Data are presented as means ± SD of 
four independent experiments (*p < 0.05 and **p < 0.01).
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to LPS/IFNγ. SLAMF5- (Figure  6A) or IRF8-silenced cells 
(Figure 6B) released significantly higher amounts of IL-1β and 
IL-23 than did control cells, implying that both SLAMF5 and 
IRF8 may function to restrain excessive inflammatory reac-
tions. On the contrary, SLAMF5-silenced or IRF8 knockdown 
cells produced less IL-12 than control cells. Remarkably, these 
experiments also showed that IL-12 production in response to 
LPS/IFNγ stimulation was fully IRF8 dependent (Figure  6B). 
The finding that loss of IRF8 replicated several changes in DC 
phenotype (Figures 1D,E and 4C,D) and cytokine production 
observed in SLAMF5-silenced cells, lends further support to a 
model in which SLAMF5 and IRF8 are part of the same regula-
tory pathway.
Taken together, data presented above identifies SLAMF5 as 
a novel cell surface-expressed regulator of DC autophagy oper-
ating via stabilization of one of the autophagy master-regulator 
transcription factors, IRF8 (Figure 7).
DiscUssiOn
SLAMF receptors regulate various stages of the immune 
response including the differentiation of innate and classical 
T  cell subsets as well as the T- and B  cell memory response 
(19, 21, 41). Consequently, in addition to antimicrobial 
responses, SLAMF receptors have been shown to contribute to 
pathological autoimmune responses, i.e., colitis and systemic 
lupus erythematosus (44–46), as well as to neuropsychiatric 
diseases with inflammatory and neurodegenerative etiologies 
(47, 48). Despite its ubiquitous expression in practically all 
hematopoietic lineages, mice carrying defective SLAMF5 alleles 
at both chromosomes have a relatively mild phenotype. The 
main defect appears to be restricted to germinal center forma-
tion, specifically due to lack of proper adhesion and functional 
interaction between T follicular helper (Tfh) and B  cells, but 
not DCs (28). However, normal DC functions in the absence 
FigUre 7 | Schematic model depicting signaling lymphocyte activation 
molecule family (SLAMF) 5-mediated modulation of autophagy and cytokine 
production in monocyte-derived dendritic cells (moDCs) via stabilization of 
interferon regulatory factor 8 (IRF8). In an ongoing infection with Gram-
negative bacteria, dendritic cells (DCs) are exposed to LPS and IFNγ that are 
known to reduce autophagy, presumably to prevent exposure of autoreactive 
T cells to self-antigens in the presence of strong co-stimulatory signals. In the 
early phase of DC activation, concomitant with the secretion of pro-
inflammatory cytokines (a), IRF8 expression is induced (B). IRF8 in turn 
promotes the production of IL-12 (c) and restores autophagy (D) to control 
overproduction of potentially self-destructive cytokines, such as IL-1β and 
IL-23 (e). We found that SLAMF5 is upregulated in response to LPS/IFNγ  
(F) and inhibits TRIM21-mediated proteasomal degradation of IRF8 (g). By 
this mechanism, SLAMF5 acts as a positive regulator of autophagy in moDC, 
likely impacting on the outcome of antimicrobial responses as well as on 
autophagy-driven pathologies.
12
Agod et al. SLAMF5 Enhances Autophagy via IRF8
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 9 | Article 62
of SLAMF5 may be explained by compensatory mechanisms 
implemented by other SLAMF members. Alternatively, appear-
ance of the unique functions of SLAMF5 may require specific 
environmental challenges, yet to be identified. In support of 
this latter scenario, SLAMF5 has been shown to regulate TCR-, 
BCR-, and FCεRI-mediated signal-transduction (26, 28, 49). 
The function of SLAMF5 in myeloid cells, however, remains 
poorly understood. In a single report, SLAMF5 knockdown was 
found to decrease LPS-induced TNF-alpha and IL-6 production 
of murine bone marrow-derived macrophages (50). In our work, 
we set up experiments to analyze the function of SLAMF5 in 
human moDCs. When SLAMF5 expression was decreased by 
80–95% using transfection of specific siRNA, human peripheral 
blood monocytes readily differentiated into moDCs, suggesting 
that SLAMF5 may not be required for the main steps of moDC 
differentiation. In addition, although SLAMF5 was shown to 
act as a survival factor in certain tumor cell lines (31), viability 
of SLAMF5-deficient moDCs appeared to be identical to that 
of control cells, suggesting that the survival-promoting effect of 
SLAMF5 may be context dependent, lineage-specific, or even 
restricted to transformed cells.
Nevertheless, production of IL-1β and IL-23 was significantly 
enhanced by cells with reduced SLAMF5 levels while IL-12 secre-
tion was diminished compared with controls. These functional 
changes occurred in the absence of altered expression of receptors 
associated with DC activation including HLA proteins or the 
co-stimulatory molecules CD40 and CD86. Thus, SLAMF5-
mediated modulation of cytokine production without affecting 
co-stimulatory receptor expression may allow DCs to alter 
polarization of naïve T cells while supporting their proliferation. 
In this regard, independent regulation of DC maturation and 
inflammatory cytokine production has been described by the 
D’Oro group in TLR ligand-activated DCs treated with the pan-
Src-kinase inhibitor PP1 or PP2 (51, 52).
More rigorous analysis of the SLAMF5-deficient moDCs 
identified a consistent, albeit moderate decrease of CD1a 
expression that together with an increase in IL-1β and IL-23 
production was reminiscent of the phenotype of DCs treated 
with autophagy inhibitors (40). Inhibition of autophagy, either 
with the PI3K inhibitor 3-methyladenine or with siRNA against 
the autophagy protein Atg7 significantly increased IL-1β pro-
duction of human PBMC stimulated with either LPS (53) or 
Mycobacterium tuberculosis (Mtb) (54). Likewise, LPS-activated 
human moDCs produced more IL-23 under such circumstances 
(55). It has also been reported that IL-1β, produced following 
autophagy inhibition in DCs, acted in an autocrine manner 
to drive IL-23 secretion and this appears to be the mechanism 
through which autophagy exerts its effects on IL-23 (55). 
In our experiments, in response to LPS/IFNγ, SLAMF5-silenced 
moDCs showed a similar increase of IL-1β and IL-23 production 
as autophagy-deficient cells, indicating that SLAMF5 may act as 
a positive regulator of autophagy in moDCs. Our hypothesis 
that SLAMF5 is a novel cell surface regulator of autophagy was 
confirmed by two complementary methods; by monitoring 
conversion of LC3 into its lipid-modified form, and monitoring 
accumulation of CYTO-ID, an autophagosome-specific dye. 
In our experiments, however, impaired autophagy was strik-
ingly accompanied by decreased IL-12 secretion, which seems 
to contradict an earlier study reporting that mice lacking the 
autophagy protein Atg5 in myeloid cells secrete higher amounts 
of IL-12 in response to infection with Mtb (56). This discrepancy, 
however, may be readily resolved by the IRF8 dependence of 
LPS/IFNγ-induced IL-12 production in macrophages (14) and, 
as our results demonstrate, in human moDCs. In addition to 
IL-12, the transcription of multiple components of the autophagy 
machinery was recently shown to be under the control of IRF8 
in murine DCs. Our work shows that, similarly to murine cells, 
IRF8 has a pivotal role in the autophagic process of human 
moDCs. Based on these findings we propose that DC autophagy 
is controlled by SLAMF5 via an IRF8-dependent mechanism. 
In support of this, we presented evidence that cross-linking with 
a SLAMF5-specific agonistic antibody significantly increased 
the autophagic flux of human moDCs both under steady-state 
conditions and following activation with LPS/IFNγ. Importantly, 
this effect was reversed by silencing IRF8 expression of moDCs. 
Several studies have demonstrated the importance of posttrans-
lational modifications in the regulation of IRF8 activity (15, 17). 
Pretreatment with the proteasome inhibitor MG132 restored 
IRF8 protein levels of SLAMF5-silenced cells indicating that 
in moDCs IRF8 is at least in part controlled by SLAMF5 via 
modulating its degradation by the proteasome.
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Taken together, data presented in this work strongly suggest 
that SLAMF5 controls the production of key inflammatory 
cytokines via regulating autophagy, mediated at least in part by 
fine-tuning proteasomal degradation of one of the autophagy 
master regulators, IRF8. Regarding the molecular machinery 
involved in the described SLAMF5-dependent increase of IRF8 
stability, we identified the E3-ubiquitin ligase TRIM21 as a 
mediator of IRF8 degradation in SLAMF5-silenced moDCs.
However compelling the mechanism of IRF8 control by the 
SLAMF5 signaling pathway in the regulation of autophagy and 
inflammatory cytokine production regulation seems, we cannot 
exclude contribution of other pathways. For example, similar to 
the mechanism described for SLAMF1 and SLAMF4, SLAMF5 
may partake in the formation of the Beclin-1/Vps34 autophagy-
associated regulatory complex (22–24). Although much of the 
molecular details of autophagy regulation are yet to be clarified, 
SLAMF5 should influence the early events of autophagy, steps 
independent of autophagosome maturation as well as mTOR, as 
neither BafA1 nor rapamycin rescued the defect seen in SLAMF5-
silenced moDCs.
Pharmacological modulation of the autophagy process is 
of great significance (57). The close to ubiquitous expression 
of SLAMF5 in hematopoietic cells provides an opportunity to 
selectively augment autophagic functions in these cells. Immune 
cell-specific autophagy regulators on one hand could decrease 
the unwanted pleiotropic effects associated with manipulation of 
systemic autophagy, and at the same time, increase cell-extrinsic 
effects of autophagy that operate in the context of host defense.
MoDCs have been reported to be present in the mammalian 
brain during infections controlling reactive T-lymphocyte 
influx and contributing to neurodegenerative processes (58). 
Furthermore, moDCs are also thought to be crucial in brain 
immunosurveillance, and key players in various neuropatholo-
gies associated with Alzheimer’s disease (AD) and Parkinson’s 
disease (59). In AD, impaired clearance of amyloid-β plaques 
and tau protein tangles was shown in an SLAMF receptor and 
Beclin-1 interactome-dependent manner reflecting on the criti-
cal involvement of defective autophagy and phagocytosis in AD 
pathogenesis (48).
Based on the central role of autophagy in antimicrobial 
immunity and inflammation, autophagy upregulation in immune 
cells can be beneficial in infectious diseases (56). In this regard, 
Garcia et al. have recently reported that autophagy was induced 
by Mtb-derived antigens in the adherent population of PBMC of 
Mtb carriers. The level of autophagy was IFNγ dependent and 
showed a positive correlation with the level of IFNγ produced by 
the patient’s PBMC (60). Moreover, the same group has shown 
earlier that T cells isolated from patients with favorable clinical 
response to Mtb (high responders) had increased expression 
of SLAMF1 compared with those derived from low responders 
(61, 62). Interestingly, they also demonstrated that IL-17 and 
SLAMF1 have opposing effects on IFNγ production in tuberculo-
sis patients (62). These findings are in line with our earlier results 
in LPS-activated moDCs showing a positive effect of SLAMF1 
on the IL-12–IFNγ axis in the context of Th1-cell differentiation 
(63). In this article, we report that SLAMF5 modifies the cytokine 
profile of LPS/IFNγ-stimulated moDCs in a manner that would 
support Th1  cell differentiation in expense to Th17  cell differ-
entiation. However, this interpretation may be overly simplistic. 
As described by Schmitt et al., IL-12 controls the differentiation of 
IL-21-producing Tfh-like cells, and induces IL-21 secretion from 
memory CD4+ T cells (64). These findings, together with the well 
documented role of SLAMF5 in the differentiation of murine 
Tfh cells imply that SLAMF5 in human DCs may also promote 
commitment of naïve CD4+ T  cells toward the Tfh lineage. 
Altogether, our findings suggest that in human DCs, SLAMF5 
supports intracellular pathogen-induced immune responses by 
both increasing the level of autophagy and by modulation of 
T-cell differentiation. Further research is required to understand 
the complexity of the underlying mechanisms, and to establish, to 
what extent, modulation of autophagy using agonistic SLAMF5-
specific antibodies may be used to improve current therapies for 
various human diseases.
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FigUre s1 | Phenotypic maturation of SLAMF5-silenced moDCs. (a) moDCs 
were exposed to 100 ng ml−1 LPS and 10 ng ml−1 IFNγ for 24 h. Cell surface 
expression of HLA-A, B, C, HLA-DQ, CD40, and CD86 was measured by flow 
cytometry; values are expressed as reléative fluorescence. Expression of the 
above cell surface receptors was measured on the CD1a+ (B) and CD1a− (c) 
subsets of control and SLAMF5-silenced moDCs. Bars show the relative 
fluorescence intensity values (D) Data are presented as means ± SD of three 
independent experiments. (*p < 0.05 and ***p < 0.001; ns, not significant).
FigUre s2 | Additional information to SLAMF5-mediated enhancement of 
dendritic cell autophagy. (a) This panel shows the uncropped version of 
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Figure 2a. (B) Analysis of basal level of autophagy in control and SLAMF5-
silenced cells. Control and SLAMF5-silenced moDCs were left untreated or 
incubated with 20 nM bafilomycin A1 (BafA1) for 2 h. LC3 and β-actin levels 
were analyzed by western blotting. In this panel, samples of BafA1-treated 
and untreated cells are run on the same gel. Please note the robust 
accumulation of LC3-II in the BafA1-treated samples! BafA1-treated samples 
are badly overexposed precluding quantitation of LC3-II readouts of 
BafA1-treated and untreated samples from the same gel. Thus, samples 
derived from BafA1-treated and untreated samples were run and analyzed 
separately. Of note, at shorter exposure times, LC3-I band is not visible on 
blots of the BafA1-treated samples. (c) Autophagosome formation was 
visualized by CYTO-ID staining followed by confocal microscopy in control and 
SLAMF5-silenced moDCs in the presence or absence of 50 μM Chloroquine, 
an inhibitor of lysosomal acidification. Representative images show 
appearance of fluorescent puncta due to vacuolar localization of CYTO-ID in 
autophagosomes. Nuclei are highlighted by Hoechst 33342 staining. FOV: 
57.4 μm × 44.9 μm.
FigUre s3 | SLAMF5 expression in IRF8 knockdown moDCs. On day 5 of 
moDC differentiation, cell surface expression of SLAMF5 in IRF8-silenced or 
control moDCs was measured by flow cytometry. Values are expressed as 
relative fluorescence and are the mean ± SD of five independent experiments 
(*p < 0.05).
FigUre s4 | Accumulation of ubiquitinated proteins in the presence of the 
proteasome inhibitor MG132. This panel shows a representative blot of control 
experiments to confirm the activity of MG132 in our experimental system. 
MoDCs were treated as described in the legend for Figure 5B. Western blot was 
developed by a ubiquitin-specific antibody as described in Section “Materials and 
Methods.”
FigUre s5 | TRIM21 expression is enhanced in response to treatment with 
LPS/IFNγ. SLAMF5 knockdown or control moDCs were exposed to 100 ng ml−1 
LPS and 10 ng ml−1 IFNγ for 8 h. TRIM21 protein levels were determined by 
western blot analysis. A representative of three independent experiments is 
shown. Bar chart on the right displays TRIM21 protein levels of SLAMF5-silenced 
or control moDCs relative to β-actin (*p < 0.05).
FigUre s6 | EAT-2 expression levels in human monocytes and moDCs. 
Western blot analysis of EAT-2 expression in monocytes and moDCs on day 5 of 
in vitro differentiation treated or not with LPS/IFNγ. A representative blot of three 
independent experiments is shown,  
with β-actin as loading control.
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